Kyntra Bio (KYNB) Exchange Rate Effect (2014 - 2026)
Kyntra Bio (KYNB) posted Exchange Rate Effect of $1000.0 for Q1 2026, up 102.04% sequentially from -$49000.0 in Q4 2025, and down 99.93% YoY from $1.4 million in Q1 2025.
Kyntra Bio (KYNB) Exchange Rate Effect (2014 - 2026) Analysis & Trends
Kyntra Bio has reported Exchange Rate Effect for 13 years, with the latest figure at $1000.0 in Q1 2026.
- Quarterly Exchange Rate Effect fell 99.93% year-over-year to $1000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$329000.0 (down 117.0% YoY) and the FY2025 annual result came in at $1.1 million, up 43.41% from the prior year.
- Exchange Rate Effect rose to $1000.0 in Q1 2026 per KYNB's latest filing, from -$49000.0 in the prior quarter.
- Over five years, Exchange Rate Effect peaked at $2.6 million in Q2 2024 and troughed at -$4.5 million in Q2 2022.
- A 5-year average of -$414705.9 and a median of -$49000.0 in 2025 frame the typical range for Exchange Rate Effect.
- The sharpest annual moves came in 2022 and 2025: Exchange Rate Effect plunged 3403.88% in 2022, then surged 530.94% in 2025.
- Over 5 years, Exchange Rate Effect stood at $2.5 million in 2022, then tumbled by 55.79% to $1.1 million in 2023, then slumped by 107.92% to -$87000.0 in 2024, then surged by 43.68% to -$49000.0 in 2025, then jumped by 102.04% to $1000.0 in 2026.
- According to Business Quant data, Exchange Rate Effect over the past three periods registered $1000.0, -$49000.0, and -$1.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Exchange Rate Effect (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -3.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -300,000.00 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -2.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.84 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -2.45 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.63 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -287,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Kyntra Bio | 30.42 Mn | 30.42 Mn | 1.47 Mn | -30,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -30,000.00 |
| Jun 30, 2026 | -30,000.00 |
| Mar 31, 2026 | 1,000.00 |
| Mar 31, 2026 | 1,000.00 |
| Dec 31, 2025 | -49,000.00 |
| Dec 31, 2025 | -49,000.00 |
| Sep 30, 2025 | -1.26 Mn |
| Sep 30, 2025 | -1.26 Mn |
| Jun 30, 2025 | 981,000.00 |
| Jun 30, 2025 | 981,000.00 |
| Mar 31, 2025 | 1.41 Mn |
| Mar 31, 2025 | 1.41 Mn |
| Dec 31, 2024 | -87,000.00 |
| Dec 31, 2024 | -87,000.00 |
| Sep 30, 2024 | -1.96 Mn |
| Sep 30, 2024 | -1.96 Mn |
| Jun 30, 2024 | 2.58 Mn |
| Jun 30, 2024 | 2.58 Mn |
| Mar 31, 2024 | 223,000.00 |
| Mar 31, 2024 | 223,000.00 |